Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Swedish Orphan Biovitrum AB (publ) (BIOVF), covering cash flow, earnings, and balance sheets.
Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement & Financial Overview
Review Swedish Orphan Biovitrum AB (publ) BIOVF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $6.46B | $7.44B | $6.89B | $5.44B |
| Cost of Revenue | $1.50B | $1.60B | $1.33B | $2.15B |
| Gross Profit | $4.97B | $5.84B | $5.56B | $3.29B |
| Gross Profit Ratio | $0.77 | $0.78 | $0.81 | $0.61 |
| R&D Expenses | $834.00M | $981.00M | $845.00M | $898.00M |
| SG&A Expenses | $2.68B | $3.19B | $1.81B | $1.75B |
| Operating Expenses | $3.61B | $4.17B | $3.52B | $2.65B |
| Total Costs & Expenses | $5.11B | $5.77B | $4.86B | $4.80B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $326.00M | $337.00M |
| Depreciation & Amortization | $938.00M | $932.00M | $924.00M | $915.00M |
| EBITDA | $2.29B | $2.59B | $2.96B | $1.55B |
| EBITDA Ratio | $0.35 | $0.35 | $0.43 | $0.29 |
| Operating Income | $1.36B | $1.66B | $2.04B | $640.00M |
| Operating Income Ratio | $0.21 | $0.22 | $0.30 | $0.12 |
| Other Income/Expenses (Net) | -$262.00M | -$225.00M | -$326.00M | -$337.00M |
| Income Before Tax | $1.10B | $1.44B | $1.71B | $275.00M |
| Income Before Tax Ratio | $0.17 | $0.19 | $0.25 | $0.05 |
| Income Tax Expense | $221.00M | $47.00M | $248.00M | $51.00M |
| Net Income | $875.00M | $1.40B | $1.46B | $224.00M |
| Net Income Ratio | $0.14 | $0.19 | $0.21 | $0.04 |
| EPS | $2.55 | $4.07 | $4.27 | $0.66 |
| Diluted EPS | $2.52 | $4.03 | $4.22 | $0.65 |
| Weighted Avg Shares Outstanding | $343.45M | $343.23M | $343.01M | $340.59M |
| Weighted Avg Shares Outstanding (Diluted) | $346.97M | $347.06M | $346.84M | $344.75M |
Over the last four quarters, Swedish Orphan Biovitrum AB (publ) achieved steady financial progress, growing revenue from $5.44B in Q2 2024 to $6.46B in Q1 2025. Gross profit stayed firm with margins at 77% in Q1 2025 versus 61% in Q2 2024. Operating income totaled $1.36B in Q1 2025, maintaining a 21% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $2.29B. Net income dropped to $875.00M, with EPS at $2.55. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan